Lead Sponsor

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

No

•1. Documented cancer of the pancreas who have failed (or are not candidates for) standard therapy
•2. ECOG Performance Status of 0 to 1
•3. Adequate organ function as defined by study-specified laboratory tests
•4. Must use acceptable form of birth control through the study and for 28 days after final dose of study drug
•5. Signed informed consent form
•6. Willing and able to comply with study procedures

•1. Currently have or have history of certain study-specified heart, liver, kidney, lung, neurological, immune or other medical conditions
•2. Clinical metabolic or laboratory abnormalities defined as Grade 3 or 4 of the National Cancer Institute's (NCI's) Common Terminology Criteria for Adverse Events (CTCAE), version 3.0
•3. Systemically active steroids
•4. Another investigational product within 28 days prior to receiving study drug
•5. Major surgery or significant traumatic injury (or unhealed surgical wounds) occurring within 28 days prior to receiving study drug
•6. Infection with HIV, hepatitis B or C at screening
•7. Pregnant or lactating
•8. Conditions, including alcohol or drug dependence, or intercurrent illness that would affect the patient's ability to comply with study visits and procedures

Related studies

NCT02600949 · Metastatic Colorectal Adenocarcinoma, Metastatic Pancreatic Ductal Adenocarcinoma, and more

NCT03050268 · Acute Leukemia, Adenomatous Polyposis, and more

NCT06423326 · Borderline Resectable Pancreatic Ductal Adenocarcinoma, Resectable Pancreatic Adenocarcinoma, and more

NCT07542041 · Pancreatic Cancer, Pancreatic Neoplasms, and more

NCT07283705 · Phase 2 Study, BMS-986504, and more

Ipilimumab +/- Vaccine Therapy in Treating Patients With Locally Advanced, Unresectable or Metastatic Pancreatic Cancer